「4/3」の検索結果
327件：41～45件目を表示
-
July 16, 2024 General Announcement: Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Senju has successfully completed Phase III clinical trials in Japan for the novel Dry Eye Disease tr
https://www.senju.co.jp/sites/default/files/content_news/2024-07/ENG_20240716.pdf -
July 16, 2024 General Announcement: Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Senju has successfully completed Phase III clinical trials in Japan for the novel Dry Eye Disease tr
https://www.senju.co.jp/sites/default/files/content_news/2024-07/ENG_20240716_0.pdf -
Senju initiated Phase III Clinical Trials in Japan for “SJP-0132” for the treatment of Dry Eye Disease The Clinical Trials use a novel compound discovered by Mochida and licensed to Senju Senju Pharma
https://www.senju.co.jp/sites/default/files/content_news/2023-03/ENG_20230322_0.pdf -
General Announcement: September 3, 2024 Senju Pharmaceutical Co., Ltd. Acquisition of Marketing Approval for “ Mytear LUMIFY” Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr.
https://www.senju.co.jp/sites/default/files/content_news/2024-08/ENG_20240903.pdf -
General Announcement: September 3, 2024 Senju Pharmaceutical Co., Ltd. Acquisition of Marketing Approval for “ Mytear LUMIFY” Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr.
https://www.senju.co.jp/sites/default/files/content_news/2024-08/ENG_20240903_0.pdf